InflaRx plans two Phase 2 izicopan trials in ANCA-associated vasculitis in 2027
IFRX•InflaRx plans two Phase 2 izicopan trials in ANCA-associated vasculitis starting in 2027, with first results expected in 2028. Its cash and marketable securities totaled €153.3 million on September 30, 2026, and are expected to fund operations through 2029.
1. Vasculitis trials planned
InflaRx plans to start two Phase 2 trials of izicopan in ANCA-associated vasculitis in 2027, with first results expected in 2028. One placebo-controlled trial will assess kidney benefits, while an open-label study will test whether izicopan can safely replace corticosteroids. An independent commercial assessment estimates peak sales potential of $1.5 billion to $2 billion in the disease.
2. Other studies and funding
The company also plans studies in kidney diseases, with initial atypical hemolytic uremic syndrome data targeted for late 2027 and IgA nephropathy data in 2028. Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, and are expected to support operations through 2029.
